# Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes

> **NCT00143520** · PHASE2,PHASE3 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 441 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Rivoglitazone
- **DRUG:** Pioglitazone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00143520
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2005-12
- **Final completion:** 2005-12
- **Target enrollment:** 441 (ACTUAL)
- **Last updated:** 2021-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00143520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00143520, "Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00143520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*